Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

NCT01532089 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

88

Enrollment

OTHER

Sponsor class

Conditions

EGFR Exon 19 Deletion Mutation
EGFR NP_005219.2:p.L858R
Lung Non-Squamous Non-Small Cell Carcinoma
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Erlotinib
DRUG: Erlotinib Hydrochloride
OTHER: Laboratory Biomarker Analysis

Sponsor

Academic and Community Cancer Research United

Collaborators

[object Object]